Rongjia Zhu1, Yue Zhu2, Kun Liu3, Xin Li2, Dezhong Chen4, Yixun Liu5, Dayong Xu6*, Yan Liu6*, Robert Chunhua Zhao1,7*
Background: COVID-19 is a new respiratory tract infectious disease caused by SARS-CoV-2. Some patients presented neurological symptoms, such as mental distress, confusion, and coma besides respiratory symptoms, which brings new challenge to cure these symptoms.
Case: Here we describe a case of COVID-19 patient with initial symptoms of feeble, somnolence, and further developed to light coma, very poor spirit but no distinct fever, cough, and dyspnea. Since the regular treatment was ineffective, this patient was enrolled and received MSC infusion. The outcome suggested that MSC was able to enhance immune function and improve the conscious disorder of the patient. This patient’s consciousness turned light coma to clear gradually since 5th day after MSC infusion without other symptoms arose. Meanwhile, her lymphocyte subgroup counts and liver function indexes had recovered close to normal. During the observation, no adverse events were detected by doctors.
Conclusion: We imply that MSC can be a safe and potential effective adjuvant therapy for COVID-19 with neurological symptoms.